Genome-Wide Analysis to Identify HLA Factors Potentially Associated With Severe Dengue

Sudheer Gupta, Ankita Agarwal, Amod Kumar and Debasis Biswas*

Regional Virology Laboratory, Department of Microbiology, All India Institute of Medical Sciences Bhopal, Bhopal, India

The pathogenesis of dengue hemorrhagic fever (DHF), following dengue virus (DENV) infection, is a complex and poorly understood phenomenon. In view of the clinical need of identifying patients with higher likelihood of developing this severe outcome, we undertook a comparative genome-wide association analysis of epitope variants from sequences available in the ViPR database that have been reported to be differentially related to dengue fever and DHF. Having enumerated the incriminated epitope variants, we determined the corresponding HLA alleles in the context of which DENV infection could potentially precipitate DHF. Our analysis considered the development of DHF in three different perspectives: (a) as a consequence of primary DENV infection, (b) following secondary DENV infection with a heterologous serotype, (c) as a result of DENV infection following infection with related flaviviruses like Zika virus, Japanese Encephalitis virus, West Nile virus, etc. Subject to experimental validation, these viral and host markers would be valuable in triaging DENV-infected patients for closer supervision owing to the relatively higher risk of poor prognostic outcome and also for the judicious allocation of scarce institutional resources during large outbreaks.

Keywords: dengue hemorrhagic fever, epitope variants, HLA association, severe dengue, GWAS

INTRODUCTION

The WHO has described Dengue as a “fast-emerging pandemic-prone” disease, whose incidence has increased 30-fold over the last 50 years (1). Up to 400 million infections are estimated to occur annually in over 100 countries, putting half of the world's population at risk (2). India too has witnessed a recent increase in the burden of dengue; with the number of cases rising by >230% in 2015 and 2016, compared to the annual average of the previous 5 years (3).

While in majority of cases, the dengue virus (DENV) infection remains subclinical or presents with mild dengue fever (DF), approximately a quarter of the infected individuals experience life-threatening forms of dengue, viz. dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS). Though early prediction of severe forms of dengue is invaluable for triaging patients who merit closer supervision and also for judicious allocation of limited health-care resources during outbreaks, till date, it has not been possible to devise appropriate markers to identify DENV-infected patients who carry a higher likelihood of developing DHF. This becomes particularly important in view of the lack of approved vaccines and definitive antiviral drugs, which make the prevention of dengue difficult and its management only supportive.

The factors responsible for disease progression in patients with DHF/DSS remain unclear. Previous studies have mostly addressed the immunopathogenesis of DHF/DSS as a function of dysregulated immune response, characterized by increased viral replication owing to the failure of host immune responses to neutralize the infecting DENV strain. The hypothesis of “T cell
antigenic sin” explains the higher viral load and increased immunopathology in severe forms of dengue by virtue of many of the dengue-specific T cells in a particular infective episode having low affinity for the infecting virus strain and higher affinity for previously encountered strains and thus leading to suppressed or delayed viral elimination (4). The severe forms of DHF/DSS are also associated with a “cytokine storm,” which results in profuse release of pro-inflammatory cytokines subsequent to the unregulated activation of Th cells by macrophages and dendritic cells (5). In view of this reported association of DHF/DSS with increased viral replication (6), we attempted to elucidate their potential predictors based on: (a) the ability of variant DENV strains to evade the cytotoxic T cell activity or to cause increased stimulation of activated Th cells (7–11), (b) compromised cytotoxic T cell activity or exaggerated Th cell activity targeting DENV strains associated with secondary infection following primary infection with heterologous DENV serotypes (5, 6, 12) or other related flaviviruses like Zika virus (ZIKV), Japanese Encephalitis Virus (JEV), West Nile virus (WNV), etc. (13, 14).

To the best of our knowledge, a comprehensive study aimed at elucidating the viral mutation markers and corresponding HLA correlates of severe outcomes of DENV infection, which is based on the different reported mechanisms of DHF etio-pathogenesis, has not been performed till date.

MATERIALS AND METHODS

Dataset

The viral proteome/polyprotein/protein sequences were retrieved from ViPR database, which is a comprehensive online resource on different pathogenic viruses (15). The dataset comprised polyprotein (whole proteome) sequences for three categories namely Serotype 1(S1), Serotype 2 (S2), Serotype 3 (S3). Each of the datasets was further classified based on the reported disease type, i.e., DF and DHF. The total number of polyproteins in each class was 584 (DF-S1), 352 (DHF-S1), 368 (DF-S2), 173 (DHF-S2), 343 (DF-S3), and 81 (DHF-S3). The polyprotein sequences for Serotype 4 was not included in the study since very few sequences for DHF-S4 (n = 2) were reported in the ViPR database.

Identification of Significant Patterns

In order to explore the epitope landscape in the protein datasets from both DF and DHF, we first generated overlapping patterns of nine amino acids from the polyproteins. Next, in order to identify the patterns having a significant different distribution between DF and DHF disease type for all four categories of serotype, fisher’s exact test was performed. Furthermore, odds ratio (OR) and relative risk were calculated for the distribution of each pattern in DF and DHF using following formula:

\[
\text{Odds Ratio}_{\text{DHF}} \text{ (OR}_{\text{DHF}}) = \frac{(A \times D)}{(B \times C)}
\]

\[
\text{Relative Risk (RR}_{\text{DHF}}) = \frac{(A \times (A + B))}{(C \times (C + D))}
\]

where A is number of DHF strains with mutant pattern; C is number of DHF strains without mutant pattern; B is number of DF strains with mutant pattern; D is number of DF strains without mutant pattern.

The patterns having significantly different distribution between DF and DHF (Fisher’s exact test, p-value < 0.05), were searched for single amino acid variants (patterns differing by single amino acid) and double amino acids variants (patterns differing by two amino acids) within the significant pattern dataset itself, using in-house scripts. This led us to pair of amino acid variants, viz. P1 series and P2 series, respectively. In order to identify single amino acid substitution, which render a pattern from DF class to DHF class, we applied filters for P1 series, i.e., OR\textsubscript{DHF} < 1 and RR\textsubscript{DHF} ≥ 1 and RR\textsubscript{DHF} ≥ 1 and OR\textsubscript{DHF} > 1 for P2 series. More precisely, a single amino acid substitution has introduced a higher risk (RR\textsubscript{DHF} ≥ 1) in peptide series P2 than peptides in P1 series (RR\textsubscript{DHF} < 1). Moreover, a similar methodology was applied with overlapping patterns of 15 amino acids, which was a required length of patterns for the HLA-II binding epitope prediction. In this case also, we compiled two series of peptides, namely P\textsubscript{s} series (OR\textsubscript{DHF} < 1 and RR\textsubscript{DHF} < 1) and P\textsubscript{b} series (OR\textsubscript{DHF} ≥ 1 and RR\textsubscript{DHF} ≥ 1) in a similar way as P1 and P2 series. Series of such peptide pairs were taken for further prediction by immune epitope prediction pipeline to identify the differential immunogenicity.

Immune Epitope Prediction Pipeline

In this study, we have employed three different immune epitope prediction algorithms to investigate the differential immune response against viral protein sequences in DF and DHF, as described below.

HLA-I-Binding Prediction

The HLA-I binding prediction was performed by the MHC I-binding prediction software available at Immune Epitope Database (IEDB) Analysis Resource (16). This algorithm is a published tool and available in standalone form, which can be easily used with large size of the dataset. In brief, this is an artificial neural network-based prediction tool for HLA-I binding regions. This server predicts the MHC binders for 55 HLA alleles; however, we have performed the study only on 27 alleles. These 27 alleles are reference alleles available at the IEDB prediction resource. Moreover, these alleles are also reported to have a role in dengue severity/protection (4).

HLA-II-Binding Prediction

Similar to HLA-I binding prediction, the HLA-II binding prediction was performed with SMM-align software available at IEDB analysis resource (16). This tool is based on a position specific weight matrix, which allows for direct prediction of HLA-binding affinities. The performance of this prediction method was estimated using fivefold cross-validation and validated on a large MHC class II benchmark data set. The tool is well cited by related authors and also available as standalone software, which makes it suitable for our study. The present study was performed on the 27 reference set of HLA-II alleles as available on the web server of HLA-II-binding prediction at IEDB analysis resource (17).
Selection of DHF-Associated HLA Binders

The output of the HLA-I and HLA-II prediction method comes in the form IC50 (nanometers) as binding affinity. Lower the IC50, higher will be affinity of a peptide to bind with the HLA molecule. As described by the authors of prediction algorithms, peptides having IC50 ≤ 50 nM are predicted as strong affinity binders, peptides with IC50 > 50 nM, but < 500 nM are considered as intermediate affinity binders and 500 nM < IC50 ≤ 5,000 nM are considered as low-affinity binders. The selection criteria for variants after HLA-I binding prediction included IC50 ≤ 50 nM (high-affinity) for P1 series and IC50 > 50 nM (intermediate/low-affinity) for P2 series with a difference of 500 nM between both the series. However, in view of the absence/scarcity of strong affinity HLA-II binding variants, the criteria for variants selection in HLA-II binding prediction was adjusted to IC50 ≤ 500 nM (intermediate/strong affinity) for P1 series and IC50 > 500 nM (low-affinity) for P2 series with a difference of 500 nM between both the series. The difference of 500 nM in the IC50s was applied randomly to increase the stringency criteria for variant selection in both HLA-I and HLA-II binders.

Similar adjustment in HLA-I binding variants selection was done in inter-serotype cross-reactivity of DENV. In absence/scarcity of strong affinity HLA-I binders we adjusted the IC50 ≤ 500 nM for P1 series.

Proinflammatory Epitope Prediction

The proinflammatory epitope prediction was performed by the ProInflam software, which is a Support Vector Machine-based algorithm (18). The server for this prediction is available at http://metagenomics.iiserb.ac.in/proinflam/. In brief, the prediction tool is based on the hybrid model of motif and dipeptide composition of the epitope. The accuracy of this model was reported as 87.6% with a Matthews Correlation Coefficient of 0.58.

Similar to single amino acid variants, filtering and immune epitope prediction strategy was applied on double amino acids variants.

RESULTS

Genome-Wide Association Study for Peptide Variants Differentially Associated With DF and DHF

We generated and retrieved a group of 9-mer peptides from the ViPR database that were preferentially associated with the occurrence of DF (Peptide 1 series). We also identified a series of naturally occurring variant peptides that have been reported to be preferentially associated with DHF, and that differed from the Peptide 1 series by a single amino acid (Peptide 2 series). Thus, Peptide 1 (P1) and Peptide 2 (P2) series demonstrated a significant differential association with DF and DHF respectively (Fisher's exact test, p-value < 0.05). From the peptides represented in these two series, the peptides belonging to each DENV protein that showed the maximum difference in odds ratios between DHF and DF [ORDHFP2-P1] are depicted in Table 1. All peptides that demonstrated differences in odds ratios between DHF and DF have been enumerated in Table S1A in Supplementary Material in a serotype-wise manner. For example, as shown in Table 1, EAEHSGTSH peptide (P1 series) of the NS2B protein of Serotype 1 had an ORDHF of 0.05 and a natural variant having A in place of T (EAEHSGASH) changed the RRDHF to 21.15 (P1 series). A similar shift in distribution can be seen in other examples; e.g., variation from ALLIVSGVF to ALLIVSGIF in NS2B of serotype 3 shifted RRDHF from 0.08 to 12.93 (Table 1). Similarly, among double amino acid variants, mutation from EQEAEHSGT to EEPEAEHSGA increases the relative risk from 0.07 to 7.13 in NS2B protein of serotype 1 (Table 1).

Development of DHF As a Consequence of Primary DENV Infection

Considering that the outcome of DHF resulted from inadequate viral clearance by cytotoxic CD4+ T cells, we were interested in identifying peptides in P1 series that showed a considerable reduction in HLA class I allele binding compared to their corresponding variants in P1 series. The variant pairs were selected such that the peptide in P1 series had ORDHF < 1 and RRDHF < 1 and strong HLA-I binding affinity (IC50 ≤ 50 nM); while its single amino acid-variant in P2 series had ORDHF ≥ 1 and RRDHF ≥ 1 and intermediate/weak HLA-I binding affinity (IC50 > 50 nM). Table 2 enlists these selected pairs of peptides that could thus influence the disease outcome in DENV infection, together with the corresponding HLA alleles in which these peptides would display such significant change in binding affinity. To exemplify, a single amino acid variation (K to R) in VTLFFLSGK peptide of serotype 1 NS4A protein shifted the RRDHF from 0.23 to 3.9 and HLA-A*03:01-binding affinity (IC50) from 33.89 nM (strong binder) to 655.49 nM (intermediate affinity binder). Similarly, in serotype 3, the mutation of LPEKKITQW peptide of NS5 to LLKKKITQW transformed it from strong binder (26.07 nM) to low-affinity binder (6,320 nM) for HLA-B*53:01. As presented in Table 2, there are 7, 4, and 7 pairs of such peptides for serotype 1, 2, and 3 respectively, which had significantly different distribution between DF and DHF as well as drastic change in HLA-I binding from strong binders to intermediate/low-affinity binders. These peptides from DENV serotypes 1, 2, and 3 bound to 7, 3, and 7 HLA-I alleles, respectively, and to an overall total of 13 unique HLA-I alleles. Among them, HLA-A*03:01 was common across all the three serotypes and HLA-B*58:01, HLA-A*02:01, and HLA-A*31:01 bound to peptides from 2 of the 3 serotypes. Among double amino acid variants, we could filter out 12 unique patterns (P2 series), which could bind to 14 HLA-I molecules out of which 8 HLA-I alleles were common to single amino acid variants (Table 3).

A similar methodology was applied for HLA-II binding prediction, which was based on a hypothesis that a mutation that renders a peptide stronger binding with HLA-II leads to higher induction of proinflammatory cytokines by CD4+ T cells. The variant pairs were selected such that the peptide in P1 series had ORDHF < 1 and low HLA-II binding affinity (IC50 > 500 nM); while its variant in P2 series had ORDHF > 1 and intermediate/strong HLA-II binding affinity (IC50 ≤ 500 nM). As an example, a mutation from T to A in AEHSNTSHNILVEVQ peptide
TABLE 1 | Peptides/patterns and their variant (single and double amino acid), associated significantly with dengue fever and dengue hemorrhagic fever (only most differing peptides per protein are shown).

| Peptide1 (P1) | RR-P1 | Peptide2 (P2) | RR-P2 | Protein | Peptide1 (P1) | RR-P1 | Peptide2 (P2) | RR-P2 | Protein |
|--------------|-------|--------------|-------|---------|--------------|-------|--------------|-------|---------|
| Single amino acid variants | Double amino acid variants |
| Serotype 1 | | | | | | | | | |
| MNINRKKTGT | 0.13 | NNQRKKTTA | 7.23 | C | NQRRKKTGQ | 0 | NNQRKKTAR | 7.23 | C |
| AAYVGLFSG | 0.11 | TAYVGSFQ | 9.63 | E | HOFGAAAYG | 0 | HOFGTAAYG | 7.23 | E |
| LRHPQGTVI | 0.19 | LRHPQGTVI | 7.2 | M | CPQITAEQP | 0.07 | CPQITETEP | 1.31 | M |
| KEKENVVR | 0.13 | KEKENEVK | 7.75 | N51 | PTDPECPPDN | 0.07 | PNTPECPPD | 5.63 | N51 |
| IMKSVGLK | 0.13 | IMKSVGLK | 7.92 | N52A | IMMLKLITE | 0.13 | IMMLKLITD | 7.92 | N52A |
| EAEEGTSIIH | 0.05 | EAEEGTSIIH | 21.15 | N52B | EEEAETHS | 0.07 | EEEAETHS | 7.13 | N52B |
| YLPAVRE | 0.15 | YLPAVRE | 8.06 | N53 | DGVHTMWH | 0.13 | ENVFHTMWH | 7.81 | N53 |
| HNSECQGGA | 0.13 | HNSECQGGA | 7.18 | N54A | ALLVMANVE | 0 | VLLWMANVE | 2.71 | N54A |
| DLRPASAWT | 0.11 | DLHPASAWT | 9.19 | N54B | GHVANENQH | 0 | GHVANENQH | 3.05 | N54B |
| EKVDTRTPR | 0.13 | EKVDTRTPR | 7.7 | N55 | AEPILRMAI | 0 | VERLKRMAI | 5.75 | N55 |
| Serotype 2 | | | | | | | | | |
| MNINRKKAR | 0.28 | MNINRKKAK | 3.53 | C | VIMILITPT | 0 | VIMILITPT | 3.53 | C |
| LPENLEYTI | 0.15 | QPNENLEYTI | 6.59 | E | VLPENLEY | 0.15 | VLPENLEY | 4.15 | E |
| AWPQHARIE | 0.22 | AWPQHARIE | 6.61 | M | EPFIMVGQO | 0.28 | EPFIMVGQO | 1.85 | M |
| DYGQFVEST | 0.18 | DYGQFVEST | 5.7 | N51 | ASPIKE | 0.18 | ASPIKE | 3.53 | N51 |
| LTSSGOKT | 0.28 | LTSSGOKT | 3.6 | N52A | LPTETLELT | 0 | LPTETLELT | 3.43 | N52A |
| AVMAVGMS | 0.17 | AVMAVGMS | 5.93 | N52B | QGFPVSSIP | 0.2 | QGFPVSSIP | 3.24 | N52B |
| ANFAERIV | 0.18 | ANFAERIV | 5.63 | N53 | RIKQKIGL | 0.2 | RIKQKIGL | 3.94 | N53 |
| AVLHTAEVG | 0.24 | AVLHTAEVG | 4.26 | N54A | KQAYTHALS | 0 | KQAYTHALS | 10.81 | N54A |
| GLQGRWPLS | 0.2 | GLQGRWPLS | 5.19 | N54B | LGFGSITTO | 0 | LGFGSITTO | 3.45 | N54B |
| FRIKEEAEAG | 0.18 | FRIKEEAEAG | 5.55 | N55 | FWELVDKER | 0.15 | FWELVDKER | 4.6 | N55 |
| Serotype 3 | | | | | | | | | |
| S0LAKFRFSK | 0.3 | S0LAKFRFSK | 3.27 | C | KKTSTCCLVM | 0 | KKTSTCCLVM | 5.34 | C |
| AILPEYGTL | 0.23 | AILPEYGTL | 4.29 | E | TEALPEYG | 0.31 | TEALPEYG | 4.43 | E |
| CVINWKGE | 0.34 | CVINWKGE | 3.89 | N51 | CPHIAEVEP | 0 | CPHIAEVEP | 5.34 | M |
| KTDWLFMTV | 0.36 | KTDWLFMTV | 3.66 | N52A | BIRPRSEK | 0.31 | BIRPRSEK | 5.34 | N51 |
| ALLIVSGF | 0.08 | ALLIVSGF | 12.93 | N52B | DMTHTLIMI | 0 | DMTHTLIMI | 5.34 | N52A |
| ADAFQGNSA | 0.29 | ADAFQGNSA | 3.43 | N53 | KNFQTMGPI | 0 | KNFQTMGPI | 3.21 | N53 |
| AHRTRNALD | 0.22 | AHRTRNALD | 4.55 | N54A | AEPILQWIA | 0.31 | AEPILQWIA | 3.19 | N54A |
| IMKSVGOSQK | 0.23 | IMKSVGOSQK | 4.34 | N54B | AEPMVHWP | 0.21 | AEPMVHWP | 5.34 | N55 |
| GKVRLR | 0.16 | GKVRLR | 6.31 | N55 | |

(Ps, series) of NS2B protein shifted the RR of DHF from 0.05 to 7.1 and IC50 for HLA-DQA1*05:01/DQB1*03:01 binding from 969 to 250 nM. With these criteria, we identified 27, 26, and 24 unique HLA-II binders for serotype 1, 2, and 3, respectively in Ps series of peptides, majority (39%) of which were from NS5 protein. The HLA-II alleles such as DRB1*03:01, DRB1*04:01, DRB1*07:01, DPB1*02:01 [for FAAGLFLRKLTSKEL from DENV serotype 2] and HLA-DRB1*11:01 for the other 2 peptides from serotype 3 could suffer from a relatively higher predilection for DHF following infection with DENV serotypes 2 and 3, respectively. Similar to the single amino acid variants, double amino acid variants were also predicted for HLA II immunogenicity. The results are included in the Table S2B in Supplementary Material.

Development of DHF Following Secondary DENV Infection With a Heterologous Serotype

We next sought to identify the peptides in Ps series that could be potentially responsible for DHF following secondary infection with heterologous serotypes of DENV. As indicated in the hypothesis of “original antigenic sin,” we observed that secondary infection with a heterologous serotype led to DHF when the T-cell reactivity in the secondary infection was inappropriately directed to antigenic targets of the serotype of DENV that caused the primary infection. We thus scanned the dataset to identify peptides, belonging to a particular serotype in Ps series, which demonstrated single amino acid variation with peptides belonging to a different serotype in Ps series and also showed significant reduction in HLA class I-binding affinity. Secondary infection with the latter serotype, if preceded by primary infection

---

Frontiers in Immunology | www.frontiersin.org April 2018 Volume 9 Article 728
Table 3: HLA-I binding double amino acid variants present differentially in dengue fever and dengue hemorrhagic fever (DHF) primary infection among different serotypes.

| Peptide1 (P1) | ORhop P1 | RR-P1 | Peptide2 (P2) | ORhop P2 | RR-P2 | Allele | P1 IC50 | P2 IC50 | Protein |
|---------------|----------|-------|---------------|----------|-------|--------|---------|---------|---------|
| **Serotype 1** |          |       |               |          |       |        |         |         |         |
| AVKSEHTGR     | 0.18     | 0.28  | AVKSEHTGR     | 5.28     | 3.38  | HLA-A*31:01  | 22.76  | 542.47  | NS3     |
| CTLFPFLRF     | 0.59     | 0.72  | CTLFPFLRF     | 1.7      | 1.38  | HLA-A*03:01  | 21.24  | 586.25  | NS1     |
| LIAMDLQEF     | 0.63     | 0.76  | LIAMDLQEF     | 1.59     | 1.31  | HLA-A*02:03  | 45.22  | 4,281.02 | C       |
| MTGTLAVFL     | 0.35     | 0.5   | MTGTLAVFL     | 2.79     | 1.97  | HLA-A*06:02  | 15.16  | 1,028.79 | NS2A    |
| SLSMTCAIV     | 0.1      | 0.43  | SLSMTCAIV     | Inf      | 2.71  | HLA-A*02:01  | 42.54  | 4,012.84 | E       |
| SLSMTCAIV     | 0.1      | 0.43  | SLSMTCAIV     | Inf      | 2.71  | HLA-A*02:03  | 21.33  | 2,289.62 | E       |
| SSMNILMNMR    | 0.08     | 0.13  | SSMNILMNMR    | 3.11     | 2.19  | HLA-A*11:01  | 14.28  | 987.08  | C       |
| VTLFLSLGIK    | 0.14     | 0.23  | VTLFLSLGIK    | 6.29     | 3.9   | HLA-A*03:01  | 33.89  | 655.49  | NS4A    |
| **Serotype 2** |          |       |               |          |       |        |         |         |         |
| LLLRKLTSK     | 0.28     | 0.51  | LLLRKLTSK     | 3.84     | 2.03  | HLA-A*03:01  | 18     | 1,054.92 | NS2A    |
| MAAILAYTI     | 0.11     | 0.38  | MAAILAYTV     | Inf      | 3.2   | HLA-B*58:01  | 28.81  | 653.28  | M       |
| MTDDIGMGW     | 0.17     | 0.35  | MTDDIGMGW     | 6.64     | 2.97  | HLA-A*01:01  | 42.8   | 2,276.8  | NS2A    |
| TVMDISIKF     | 0.13     | 0.19  | TVMDISIKR     | 7.7      | 5.14  | HLA-A*03:01  | 42.24  | 699.99  | NS5     |
| **Serotype 3** |          |       |               |          |       |        |         |         |         |
| CTNTFVLLK     | 0.2      | 0.3   | CTNTFVLLK     | 5.21     | 3.31  | HLA-A*08:01  | 39.9   | 590.5   | E       |
| IMKSVGQTR     | 0.12     | 0.23  | IMKSVGQTR     | 8.75     | 4.34  | HLA-A*03:01  | 32.39  | 648.08  | NS4B    |
| KVDFNFTMGW    | 0.51     | 0.59  | KVDFNFTMGW    | 2.67     | 2.12  | HLA-A*02:01  | 25.72  | 1,527.79 | NS1     |
| LPEKKTOW      | 0.36     | 0.45  | LPEKKTOW      | 5.06     | 3.25  | HLA-B*53:01  | 26.07  | 6,320.04 | NS5     |
| MALKLTQF      | 0.25     | 0.35  | MALKLTQF      | 5.31     | 3.38  | HLA-B*35:01  | 29.82  | 728.94  | NS2A    |
| MALKLTQF      | 0.25     | 0.35  | MALKLTQF      | 5.31     | 3.38  | HLA-B*35:01  | 48.28  | 1,256.71 | NS2A    |
| SQGAGWSLIK    | 0.42     | 0.5   | SQGAGWSLIK    | 2.49     | 2.08  | HLA-A*31:01  | 44.63  | 703.42  | NS5     |

with the former serotype, would hence lead to an exaggerated response to the peptides encountered in primary infection and potentially suboptimal CD8+ T cell response toward the peptide variants of secondary infection and subsequently to higher viral titers associated with DHF. We, accordingly, observed a total of three peptides belonging to serotype 1 DENV polyprotein (P1 series) that demonstrated a single amino acid variation and a significant reduction in HLA class I binding affinity with peptides in serotype 2 DENV polyprotein (P2 series) and subsequent compromise in CD8+ cytotoxic T cell reactivity. We surmised that hosts bearing HLA class 1 alleles that demonstrated such variable binding affinity could be prone to suffer from DHF if they experienced secondary infection with DENV serotype 2 following primary infection with DENV serotype 1.
For example, peptide MVTLYLGVM found in serotype 1, belonging to P1 series (RR_{SHF} = 0.13; HLA-B*35:01 binding IC50 = 260.49 nM) demonstrated single amino acid variation with peptide IVTLYLGVM in serotype 2, belonging to P2 series (RR_{SHF} = 3.16; HLA binding IC50 for same allele = 2,719.9 nM); thereby rendering hosts with HLA-B*35:01 vulnerable to DHF in case of secondary infection with serotype 2 following primary infection with serotype 1 (Table 4). We similarly computed the HLA class I alleles that could account for DHF following different combinations of primary and secondary infection with other DENV serotypes (Table 4). In all, we identified three, four, one, two, and three peptide pairs and three, five, one, and four corresponding HLA-1 alleles for S1–S2, S1–S3, S2–S1, S2–S3, and S3–S2 combinations of serotypes, respectively (former figure representing the serotype causing primary infection and the latter figure representing the serotype of secondary infection). Notably, a majority of the peptide pairs/variants belonged to non-structural proteins. HLA-B*35:01 was found potentially associated with DHF following primary infection with serotype 1 and secondary infection with either serotype 2 or serotype 3 (Table 4). Similar study was carried out with double amino acid variants and the results are shown in Table S3 in Supplementary Material.

Moreover, exploring the HLA-II-binding prediction, we found a total of four peptides, which showed stronger HLA-II binding in P1 series and had a higher odds ratio-relative risk for DHF (Table S4A in Supplementary Material). Two peptides were found to be cross reactive HLA binder in secondary infection with serotype 3 following a previous infection with serotype 1. Similarly, one peptide each was found for S2–S1, and S3–S1 combinations of serotypes. The HLA-II alleles that could be incriminated for DHF prediction included DRB1*07:01, DRB1*11:01, DRB5*01:01, DRB1*04:01. Moreover, considering double amino acid variants, higher numbers of peptide variants were observed. The variants are listed in the Table S4B in Supplementary Material.

### Development of DHF as a Result of DENV Infection Following Infection With Related Flaviviruses

In view of recent reports suggesting worsening of DENV infection following previous exposure to other cross-reactive flaviviruses, we sought to identify strong HLA binders in other human flaviviruses that demonstrated single amino acid variation with DENV peptides having low HLA class I binding affinity. We found 153 such unique peptides in other human flaviviruses, which are enumerated in Table S5A in Supplementary Material. Among all such peptides of DENV, the maximum number of cross reactive variants was from DENV serotype 2. For example, variants of NS5 protein peptide (AGWDTRITR) in JEV, Kunjin virus (KUNV), WNV demonstrated strong HLA-A*31:01 binding (IC50 = 36.86 nM); while four different variants of this peptide in DENV (AGWDTRITAR, AGWDTRITER, AGWDTRITIE, and AGWDTRITIE) had very low-affinity for HLA-A*31:01 binding (IC50 > 100,700 nM). Similarly, WMTTEDMLK, WMTTEDMLST, WMTTEDMLIK peptide variants of DENV were found to be low-affinity binders for HLA-A*02 and single amino acid variant of these peptides (WMTTEDMLY), which is found in ZIKV, mounted strong binding to the same allele. Among all such peptides of DENV, a maximum number of cross reactive variants was from DENV serotype 2. Likewise, HLA-I alleles such as A*68:02, A*68:01, A*02:03, A*02:01, A*31:01, and A*03:01 were among most vulnerable alleles, which could bind to cross reactive epitopes present in DENV (Table S5A in Supplementary Material).

### Table 4

| Peptide1 (P1) | OR_{SHF} | P1 | RR-P1 | Peptide2 (P2) | OR_{SHF} | P2 | RR-P2 | Allele | P1 IC50 | P2 IC50 | Protein |
|---------------|----------|----|-------|---------------|----------|----|-------|--------|---------|---------|----------|
| Serotype 1 (P1)–Serotype 2 (P2) |
| HWFSRENSE | 0 | 0 | HWFSRENSE | 11.43 | 4.88 | HLA-A*23:01 | 157.47 | 1,600.17 | NS5 |
| HWFSRENSF | 0 | 0 | HWFSRENSFL | 11.43 | 4.88 | HLA-A*24:02 | 311.83 | 3,174.51 | NS5 |
| MPPEKCDTL | 0.1 | 0.16 | MPPEKCDTL | 7.84 | 3.59 | HLA-A*35:01 | 173.15 | 1,964.36 | NS5 |
| MVTLYLGVM | 0.08 | 0.13 | MVTLYLGVM | 6.45 | 3.16 | HLA-A*35:01 | 260.49 | 2,719.9 | E |
| Serotype 1 (P1)–Serotype 3 (P2) |
| GLKRGETTK | 0.7 | 0.81 | GLKRGETTH | 3.52 | 2.6 | HLA-A*03:01 | 302.95 | 1,280.96 | NS5 |
| TQMCDDL | 0.08 | 0.14 | TQMCDDL | 5.45 | 3.43 | HLA-B*15:01 | 193.35 | 806.98 | NS5 |
| YGWNLKLF | 0 | 0 | YGWNLKLF | 4.59 | 2.79 | HLA-A*35:01 | 379.88 | 1,620.28 | NS5 |
| YGWNLKL | 0 | 0 | YGWNLKL | 4.59 | 2.79 | HLA-B*35:01 | 260.49 | 2,719.9 | E |
| Serotype 2 (P1)–Serotype 1 (P2) |
| GVTLYLGV | 0.33 | 0.43 | GVTLYLGV | 10.25 | 6.07 | HLA-A*68:02 | 451.93 | 4,736.82 | E |
| Serotype 2 (P1)–Serotype 3 (P2) |
| KTRANDWDF | 0.09 | 0.21 | KTRANDWDF | 5.36 | 3.36 | HLA-B*58:01 | 346.35 | 1,339.6 | NS3 |
| MEKASIEF | 0.25 | 0.39 | MEKASIEF | 5.45 | 3.43 | HLA-B*14:02 | 432.74 | 3,429.25 | NS1 |
| MEKASIEF | 0.25 | 0.39 | MEKASIEF | 5.45 | 3.43 | HLA-B*14:03 | 382.64 | 4,095.61 | NS1 |
| Serotype 3 (P1)–Serotype 2 (P2) |
| ITHYAIIGP | 0.19 | 0.3 | ITHYAIIGP | 15.48 | 2.81 | HLA-A*30:01 | 228.93 | 1,129.99 | NS4B |
| RSLINIGEEF | 0.18 | 0.29 | RSLINIGEEF | 4.14 | 3.11 | HLA-A*32:01 | 480.85 | 5,554.34 | NS5 |
| VTRGAVLTH | 0.24 | 0.34 | VTRGAVLTH | 3.84 | 2.03 | HLA-A*30:02 | 299.05 | 8,713.44 | NS3 |
| VTRGAVLTH | 0.24 | 0.34 | VTRGAVLTH | 3.84 | 2.03 | HLA-B*15:01 | 76.9 | 4,253.92 | NS3 |
Likewise, we also explored the immunological basis for worsening of the clinical outcome of other flavivirus infections following a previous episode of DENV infection. We identified 127 such peptide variants in DENV, which are single amino acid variant to epitopes (157 in number) present in other human flaviviruses. For example, as shown in Table S7A in Supplementary Material, LVIMDEAHF peptide of NS3 protein of DENV (serotype 3) was found to bind strongly (IC50 = 38.3 nM) to HLA-B*15:01 and thus mount a strong cytotoxic T cell response. However, L1IMDEAHF, L1NIMDEAHF, and L1YMDEAHF found in WNV, Spondweni virus (SPONV), and ZIKV respectively, had a lower binding affinity to the same allele (IC50 values of 600.9, 591.4, and 1,712.7 nM, respectively). This led us to speculate that in hosts possessing HLA-B*15:01 allele, previous infection with DENV might worsen the outcome of secondary infection with WNV, SPONV, or ZIKV. A similar observation was made in HLA-II binders present in DENV, which could worsen the secondary infection with other human flaviviruses. We found 240 cross reactive HLA-II binders in DENV (Pₘ series), which had a stronger binder in other flaviviruses (Pₘ series). A total of 38 of these 240 peptides were predicted proinflammatory in Pₘ series and non-inflammatory in Pₘ series.

The double amino acid variants demonstrating same phenomenon have been shown in Tables S7B and S8B in Supplementary Material for HLA I and HLA II, respectively.

DISCUSSION

In this study, we undertook a genome-wide analysis of DENV for identification of HLA-associated disease markers that could be associated with severe outcomes like DHF in the event of infection with DENV strains bearing specific variant sequences. This identification was based on the following three hypotheses that are commonly suggested as the basis of DHF pathogenesis: (a) primary infection with DENV manifesting as DHF, owing to compromised CTL response or exaggerated Th response (11), (b) secondary infection with heterologous DENV serotype precipitating DHF owing to non-neutralizing, cross reactive host response (5), and (c) DHF developing as a complication of secondary DENV infection following primary infection with other flaviviruses (13, 14), through the same mechanism as described in (b). On the basis of these three hypotheses, we have worked out a set of DENV genome variants that carry a significantly higher likelihood of causing DHF in patients possessing a certain set of high-risk HLA alleles.

The validity of our approach is borne out by previous observational studies reporting the association of these HLA alleles with DHF. Among the HLA class I alleles identified based on hypothesis (a) (as enlisted in Table 2), a total of 9 HLA-A and 3 HLA-B alleles were found to cause DHF on account of compromised CTL response, following infection with viral mutants involving different structural and non-structural proteins. Although the reports of HLA alleles for DHF in primary infection are limited, HLA-A*01 have been reported to be associated with DHF in primary DENV infection (WHO Dengue Bulletin vol. 39, Dec 2017). Similarly, 8 HLA-A and 5 HLA-B alleles have been identified in our study which could lead to DHF through hypothesis outlined in (b). Of
them, 3 HLA-A [A*31 (19), A*32 (20), and A*30 (20)] and 3 HLA-B (B*44 (21), B*15 (22), and B*35:01 (23) have been associated with DHF in previous studies. Other flaviviruses such as Yellow Fever virus (YFV), KV, Murray Valley encephalitis virus (MVEV), JEV, St. Louis encephalitis virus (SLEV), WNV, tick-borne encephalitis virus (TBEV), etc., have been shown to be antigenically related with DENV (24). Such antigenic similarity has the potential to worsen the outcome of subsequent DENV infection if preceded by the previous infection with other flaviviruses (13). In our study with single amino acid variants, we identified a total of 15 HLA-A and 10 HLA-B alleles to be associated with DHF in the context of previous flaviviral infection. Although, there are limited studies investigating occurrence of DHF with a prior infection of other flaviviruses such as A*31 (22), A*02:03 (22), A*01 (25), A*26 (20), A*68 (20), A*32 (20), A*30 (20), and B*44 (21), B*15 (22), B*35:01 (23), B*40 (19), B*53 (19). Similarly, the previous infection with DENV has also been shown to enhance disease severity in case of secondary infection with other flaviviruses like ZIKV (26, 27).

Among single amino acid variants that were differentially associated with DHF, peptide variants NYADRRWC and YILRDVSKK of NS5 protein of DENV serotype 2 were found to be significantly associated with DHF in our study (Table S1A in Supplementary Material) and they have also been reported to be recognized preferentially by CD8+ T lymphocytes of DHF patients in a previous study (28). Similarly, an HLA-II binder GYILRDVSKKEGGAM identified by us (Table S2A in Supplementary Material) contains the YLRLDVSKK epitope reported by Loke et al. (28). Furthermore, cross-reactive T cell epitopes in the region of NS3 (160-173) have been shown between all DENV serotypes, YFV, WNV, JEV, MVEV, and KV by Kurane et al. (29).

To validate our finding regarding potential association of selected HLA alleles with severe outcomes following DENV infection, we explored the EDB database and retrieved 13 publications within which four unique HLA alleles were reported for such association. Among them, HLA-A24 (30–32), HLA-B7 (30, 33, 34), and HLA-DR15 (33) have been reported by previous authors to be associated with severe outcomes following secondary DENV infection. Remarkably, in our study too, we found these HLA alleles to be potentially associated with DHF following secondary DENV infection (HLA-A24 listed in Table 4; HLA-B7 listed in Table S5A in Supplementary Material; HLA-DR15 listed in Table S2B in Supplementary Material). In addition, we found that HLA-B7 allele could trigger DHF in patients having prior infection with related flaviviruses like Kedougou virus (KEDV), JEV, WNV, SLEV, TBEV. Similarly, in sync with our reported observation, HLA-A11 allele (Tables 2 and 3) has been reported by other authors to be associated with severe DENV outcome following both primary and secondary infections. These corroborations between our study and previous literature are summarized in Table S9 in Supplementary Material.

Our study suffered from several limitations. First, the study was based only on existing genomic data available in the public database and the analysis was performed irrespective of geographical location. As a result, DENV serotype 4 could not be included in the study since only two sequences for DHF-associated serotype 4 was available in the database. Second, despite the presence of a vast number of HLA alleles in the human population, the study was restricted to the reference alleles reported in IEDB resource. Moreover, the immune-pathogenesis of DHF is multifactorial and difficult to simulate. Our study was based on the consideration of three different hypotheses, which might not be completely representative of the highly complex immune interactions involved in the causation of DHF. Although we have worked both on single and double amino acid mutations, owing to the occurrence of single amino acid variations as the commonest mutations in viral genomes (35), we focused only on single amino acid variations in this study. Apart from proclaiming usefulness and limitations of our study, we understand that extensive experimental validation of markers identified in this study would be required prior to its application in the clinical scenario.

CONCLUSION

In this study, we have performed genome-wide association analysis to identify viral antigenic variants and corresponding risk alleles, which are differentially associated with DHF. Subject to experimental validation, application of such viral and host markers in clinical settings would lead to the judicious utilization of scarce health-care resources in remote peripheral settings and would also be helpful in outbreak situations.

AUTHOR CONTRIBUTIONS

SG performed the experiments. DB and SG conceived the project. DB, SG, AA, and AK interpreted the data and wrote the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00728/full#supplementary-material.

REFERENCES

1. WHO. World Health Organization. Dengue 2013. (2013). Available from: http://www.who.int/denguecontrol/en (Accessed: November 14, 2014).
2. CDC. CDC 2016. (2016). Available from: https://www.cdc.gov/dengue/resources/healthcarepract.pdf (Accessed: August 25, 2017).
3. NVBDCP. (2016). Available from: http://nvbdcp.gov.in/den-cd.html (Accessed: August 25, 2017).
4. Weiskopf D, Angelo MA, De Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 110:E2046–53. doi:10.1073/pnas.1305227110
5. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasananawathana S, Tangthawornchaikul N, Chairunsiri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med (2003) 9:921–7. doi:10.1038/nmm887
6. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev (2009) 22:564–81. doi:10.1128/CMR.00035-09
7. Streathfield R, Bulby G, Sinclair D. A primary dengue 2 epidemic with spontaneous haemorrhagic manifestations. Lancet (1993) 342:560–1. doi:10.1016/0140-6736(93)90692-F
8. Anantapreecha S, Chanama S, A-nuegoonpipat A, Naemkhunthot S, Sa-Ngasang A, Sawapanyalert P, et al. Serological and virological features of...
dengue fever and dengue haemorrhagic fever in Thailand from 1999 to 2002. *Epidemiol Infect* (2005) 133:563–7. doi:10.1017/S0950268804003541
9. Vejbsaya S, Luangtrakrungphol P, Luangtrakrungphol K, Kalayanarooj S, Vaughan DW, Endy TP et al. TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais. *J Infect Dis* (2009) 199:1442–8. doi:10.1086/597422
10. Costa VF, Fagundes CT, Souza DG, Teixeira MM. Inflammatory and innate immune responses in dengue infection: protection versus disease induction. *Am J Pathol* (2013) 182:1950–61. doi:10.1016/j.ajpath.2013.02.027
11. Khurram M, Qayyum W, Hassan SJ, Muntau S, Bushra HT, Umar M. Dengue hemorrhagic fever: comparison of patients with primary and secondary infections. *J Infect Public Health* (2014) 7:489–95. doi:10.1016/j.jiph.2014.05.005
12. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srivattakithchakorn A, Yoon IK, et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. *PLoS Negl Trop Dis* (2010) 4:e617. doi:10.1371/journal.pntd.0000617
13. Anderson KB, Gibbons RV, Thomas SJ, Rothman AL, Nisalak A, Berkelman RL, et al. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. *PLoS Negl Trop Dis* (2011) 5:e1311. doi:10.1371/journal.pntd.0001311
14. Li C, Bai X, Meng R, Shaozhou H, Zhang Q, Hua R, et al. Identification of a newly broad cross-reactive epitope within domain III of the duck tilebivirus E protein. *Sci Rep* (2016) 6:36288. doi:10.1038/srep36288
15. Pickett RE, Sadat EL, Zhang Y, Nisalak A, Hart V, et al. VIPR: an open bioinformatics database and analysis resource for virology research. *Nucleic Acids Res* (2012) 40:D593–8. doi:10.1093/nar/gkr859
16. Fleri W, Paul S, Dhanda SK, Mahajan S, Xu X, Peters B, et al. The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. *Front Immunol* (2017) 8:278. doi:10.3389/fimmu.2017.00278
17. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different super-types and a surprising degree of repertoire sharing across super-types. *Immunogenetics* (2011) 63:325–39. doi:10.1007/s00251-011-0513-0
18. Gupta S, Madhu MK, Sharma AK, Sharma VK. Proflavam: a webserver for the prediction of proinflammatory antigenicity of peptides and proteins. *J Transl Med* (2016) 14:178. doi:10.1186/s12976-016-0928-3
19. Malavigne GN, Rostron T, Rohanachandita LT, Jayaratne SD, Fernando N, De Silva AD, et al. HLA class I and class II associations in dengue viral infections in a Sri Lankan population. *PLoS One* (2011) 6:e20581. doi:10.1371/journal.pone.0020581
20. Appanna R, Ponnampalavanar S, Lum Chai See L, Sekaran SD. Susceptible and protective HLA class I alleles against dengue fever and dengue hemorrhagic fever patients in a Malaysian population. *PLoS One* (2010) 5:e23029. doi:10.1371/journal.pone.0012309
21. Xavier Euriro De Alencar L, De Mendonca Braga-Neto U, Jose Moura Do Nascimento E, Tenorio Cordeiro M, Maria Silva A, Alexandre Antunes De Brito C, et al. HLA-B*44 is associated with dengue severity caused by DENV-3 in a Brazilian population. *J Trop Med* (2013) 2013:648475. doi:10.1155/2013/648475
22. Stephens HA. HLA and other gene associations with dengue disease severity. *Curr Top Microbiol Immunol* (2010) 338:99–114. doi:10.1007/978-3-642-02215-9_8
23. Mercado ES, Espino FE, Perez ML, Bilao JM, Bajaro JD, Huy NT, et al. HLA-A*33:01 as protective allele for severe dengue in a population of Filipino children. *PLoS One* (2015) 10:e0115619. doi:10.1371/journal.pone.0115619
24. Vaughan K, Greenbaum J, Blythe M, Peters B, Sette A. Meta-analysis of all current immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. *Viral Immunol* (2010) 23:259–84. doi:10.1089/vim.2010.0006
25. Monteiro SP, Brasil PE, Cabello GM, Souza RV, Brasil P, Georg I, et al. HLA-A*01 allele: a risk factor for dengue haemorrhagic fever in Brazil's population. *Mem Inst Oswaldo Cruz* (2012) 107:224–30. doi:10.1590/S0074-02762012000200012
26. Paul LM, Carlin ER, Jenkins MM, Tan AL, Barcellona CM, Nicholson CO, et al. Dengue virus antibodies enhance Zika virus infection. *Clin Transl Immunol* (2016) 5:e117. doi:10.1038/cit.2016.72
27. Cohen J. Dengue may bring out the worst in Zika. *Science* (2017) 355:1362. doi:10.1126/science.355.6332.1362
28. Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, White NJ, et al. Strong HLA class I – restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? *Infect Dis* (2001) 184:1369–73. doi:10.1086/342320
29. Kurane I, Omamoto Y, Dai LC, Zeng LL, Brinton MA, Ennis FA. Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8- cytotoxic T lymphocyte clones. *J Gen Virol* (1995) 76(Pt 9):2243–9. doi:10.1099/0022-1317-76-9-2243
30. Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, Thao Le TT, et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. *J Virol* (2005) 79:5665–75. doi:10.1128/JVI.79.9.5665-5675.2005
31. Mongkolpapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? *Immunol* (2006) 176:3821–9. doi:10.4049/immunol.176.6.3821
32. Duan Z, Guo J, Huang X, Liu H, Chen X, Jiang M, et al. Identification of cytotoxic T lymphocyte epitopes in dengue virus serotype 1. *J Virol* (2015) 87:1077–89. doi:10.1128/JVI.01467
33. Mathew A, Kurane I, Green S, Stephens HA, Vaughan DW, Kalayanarooj S, et al. Predominance of HLA-restricted cytotoxic T lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. *J Virol* (1998) 72:3999–4004.
34. Zivna I, Green S, Vaughan DW, Kalayanarooj S, Stephens HA, Chandanayangyong D, et al. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. *Immunol* (2002) 168:5959–65. doi:10.4049/immunol.168.11.5959
35. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral mutation rates. *J Virol* (2010) 84:9733–48. doi:10.1128/JVI.00694-10

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Gupta, Agarwal, Kumar and Biswas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.